**Supplementary Table S2**. Post-progression therapies according to treatment arm.

|  |  |  |
| --- | --- | --- |
| **Agent** | **Arm A**  **n = 43 (%)** | **Arm B**  **n = 43 (%)** |
| Irinotecan | 22 (51) | 5 (12) |
| Temozolomide (off-label) | 0 (0) | 13 (30) |
| Oxaliplatin | 1 (2) | 6 (14) |
| Fluoropyrimidine | 22 (51) | 12 (30) |
| Bevacizumab/Aflibercept | 7 (16) | 4 (9) |
| Regorafenib | 4 (9) | 12 (30) |
| Trifluridine/Tipiracil | 7 (16) | 7 (16) |